{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:26:40Z","timestamp":1757611600117,"version":"3.44.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"5-6","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.canrad.2025.104706","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T07:00:56Z","timestamp":1755241256000},"page":"104706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypofractionated radiotherapy in the management of rectal tumours"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2679-9709","authenticated-orcid":false,"given":"Marie-Ad\u00e9la\u00efde","family":"Ossedat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8641-6362","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Durand-Labrunie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.canrad.2025.104706_bib0125","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13014-018-1040-z","article-title":"The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies","volume":"13","author":"van Leeuwen","year":"2018","journal-title":"Radiat Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104706_bib0130","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ijrobp.2007.03.046","article-title":"Moderately low alpha\/beta ratio for rectal cancer may best explain the outcome of three fractionation schedules of preoperative radiotherapy","volume":"69","author":"Suwinski","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"10.1016\/j.canrad.2025.104706_bib0135","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1200\/JCO.2011.40.1836","article-title":"Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years","volume":"30","author":"Sauer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.canrad.2025.104706_bib0140","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1470-2045(11)70097-3","article-title":"Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial","volume":"12","author":"van Gijn","year":"2011","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.canrad.2025.104706_bib0145","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/bjs.5506","article-title":"Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer","volume":"93","author":"Bujko","year":"2006","journal-title":"Br J Surg"},{"issue":"31","key":"10.1016\/j.canrad.2025.104706_bib0150","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1200\/JCO.2012.42.9597","article-title":"Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04","volume":"30","author":"Ngan","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.canrad.2025.104706_bib0155","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrab137","article-title":"Radiotherapy regimens for rectal cancer: long-term outcomes and health-related quality of life in the Stockholm III trial","volume":"5","author":"Erlandsson","year":"2022","journal-title":"BJS Open"},{"key":"10.1016\/j.canrad.2025.104706_bib0160","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2022.11.020","article-title":"Comparison of short course radiotherapy with chemoradiotherapy for locally advanced rectal cancers in the elderly: a multicentre, randomised, non-blinded, phase 3 trial","volume":"180","author":"Fran\u00e7ois","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2025.104706_bib0165","doi-asserted-by":"crossref","first-page":"100067","DOI":"10.1016\/j.esmogo.2024.100067","article-title":"Efficacy and safety of short-course radiotherapy versus total neoadjuvant therapy in older rectal cancer patients: a randomised pragmatic trial (SHAPERS)","volume":"4","author":"Sa\u00fade-Conde","year":"2024","journal-title":"ESMO Gastrointest Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104706_bib0170","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2025.104706_bib0175","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1097\/SLA.0000000000005799","article-title":"Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial","volume":"278","author":"Dijkstra","year":"2023","journal-title":"Ann Surg"},{"issue":"15","key":"10.1016\/j.canrad.2025.104706_bib0180","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1200\/JCO.21.01667","article-title":"Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR)","volume":"40","author":"Jin","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.canrad.2025.104706_bib0185","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.annonc.2024.06.019","article-title":"Total neoadjuvant therapy with mfolfirinox versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial","volume":"35","author":"Conroy","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104706_bib0190","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S2468-1253(19)30410-8","article-title":"Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial","volume":"5","author":"Rullier","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104706_bib0195","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S2468-1253(20)30333-2","article-title":"Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study","volume":"6","author":"Bach","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.canrad.2025.104706_bib0200","doi-asserted-by":"crossref","first-page":"S1170","DOI":"10.1016\/S0167-8140(25)00493-1","article-title":"1489 STAR-TREC (NCT02945566): a randomised phase II\/III trial of CRT versus 5\u00d75Gy SCRT for organ preservation in early\/intermediate risk rectal cancer","volume":"206","author":"Marijnen","year":"2025","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2025.104706_bib0205","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2468-1253(22)00392-2","article-title":"Neoadjuvant chemoradiotherapy with radiation dose escalation with contact X-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial","volume":"8","author":"G\u00e9rard","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.canrad.2025.104706_bib0210","doi-asserted-by":"crossref","first-page":"e076866","DOI":"10.1136\/bmjopen-2023-076866","volume":"13","author":"Geubels","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.canrad.2025.104706_bib0215","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.esmogo.2023.08.002","article-title":"Phase III trial of short-course radiotherapy followed by capoxiri versus capox in locally advanced rectal cancer: the ENSEMBLE trial","volume":"1","author":"Watanabe","year":"2023","journal-title":"ESMO Gastrointest Oncol"},{"issue":"23","key":"10.1016\/j.canrad.2025.104706_bib0220","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa2404512","article-title":"Nonoperative management of mismatch repair-deficient tumors","volume":"392","author":"Cercek","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.canrad.2025.104706_bib0225","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41591-024-03360-5","article-title":"Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial","volume":"31","author":"Yang","year":"2025","journal-title":"Nat Med"},{"issue":"Suppl","key":"10.1016\/j.canrad.2025.104706_bib0230","doi-asserted-by":"crossref","first-page":"S1161","DOI":"10.1016\/S0167-8140(25)04358-0","article-title":"837 Preoperative short-course radiotherapy followed by chemotherapy and PD-1 inhibitor for locally advanced rectal cancer: phase II results of STELLAR II","volume":"206","author":"Tang","year":"2025","journal-title":"Radiother Oncol"},{"issue":"10","key":"10.1016\/j.canrad.2025.104706_bib0235","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.annonc.2024.06.015","article-title":"Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial","volume":"35","author":"Lin","year":"2024","journal-title":"Ann Oncol"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.canrad.2025.104706_bib0240","doi-asserted-by":"crossref","first-page":"S1163","DOI":"10.1016\/S0167-8140(25)00295-6","article-title":"1116 PRIME-RT: durvalumab with extended neoadjuvant regimens in locally advanced rectal cancer (LARC): a randomised phase II trial","volume":"206","author":"Roxburgh","year":"2025","journal-title":"Radiother Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825001222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825001222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:41:50Z","timestamp":1756932110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321825001222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":24,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1278321825001222"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104706","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypofractionated radiotherapy in the management of rectal tumours","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104706","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104706"}}